Medical Oncology Of Respiratory, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Front Immunol. 2023 Aug 8;14:1218258. doi: 10.3389/fimmu.2023.1218258. eCollection 2023.
Previous studies revealed that Programmed cell death protein 1 (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus anti-angiogenic agents had extensive anti-tumor activities. However, almost all studies on the efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small cell lung cancer are non-randomized controlled trials with small sample sizes, which might lead to a lack of effective metrics to assess the effectiveness and safety of the therapeutic regimen. Here, this meta-analysis aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small cell lung cancer.
A single-arm meta-analysis was performed, and published literature from PubMed, Web of Science and Embase databases as of January 13, 2023, was systematically retrieved. We used the Cochrane risk of bias tool and methodological index for non-randomized studies (MINORS) Methodological items to evaluate the quality of eligible clinical trials. Outcomes including overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted for further analysis. The random effect model is used to calculate the pooled parameters.
19 studies (16 were non-comparative single-arm clinical trials and 3 were randomized controlled trials) were enrolled in this meta-analysis. In terms of tumor response, the pooled ORR and DCR were 22.4% (95% CI, 16.6-28.1%) and 76.8% (95% CI, 72.6-81.1%), respectively. With regard to survival analysis, the pooled PFS and OS were 5.20 (95% CI, 4.46-5.93) months and 14.09 (95% CI, 13.20-14.97) months, respectively. The pooled grade ≥3 adverse effect (AE) rate was 47.6% (95% CI, 33.1-62.0%).
PD-1/PD-L1 inhibitors plus anti-angiogenic agents has promising efficacy and safety as second or later-line treatment in patients with advanced non-small cell lung cancer.
https://www.crd.york.ac.uk/prospero/, identifier CRD42023407559.
先前的研究表明，程序性死亡蛋白 1（PD-1）/程序性死亡配体蛋白 1（PD-L1）抑制剂联合抗血管生成药物具有广泛的抗肿瘤活性。然而，几乎所有关于 PD-1/PD-L1 抑制剂联合抗血管生成药物作为晚期非小细胞肺癌二线或更后线治疗的疗效和安全性的研究均为样本量较小的非随机对照试验，这可能导致缺乏评估治疗方案有效性和安全性的有效指标。在这里，这项荟萃分析旨在评估 PD-1/PD-L1 抑制剂联合抗血管生成药物作为晚期非小细胞肺癌二线或更后线治疗的疗效和安全性。
进行了一项单臂荟萃分析，并系统地检索了截至 2023 年 1 月 13 日来自 PubMed、Web of Science 和 Embase 数据库的已发表文献。我们使用 Cochrane 偏倚风险工具和非随机研究方法学指数（MINORS）方法学项目来评估合格临床试验的质量。提取总缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和不良事件（AE）等结局进行进一步分析。使用随机效应模型计算汇总参数。
这项荟萃分析纳入了 19 项研究（16 项为非比较性单臂临床试验，3 项为随机对照试验）。在肿瘤反应方面，汇总的 ORR 和 DCR 分别为 22.4%（95%CI，16.6-28.1%）和 76.8%（95%CI，72.6-81.1%）。关于生存分析，汇总的 PFS 和 OS 分别为 5.20 个月（95%CI，4.46-5.93 个月）和 14.09 个月（95%CI，13.20-14.97 个月）。汇总的≥3 级不良事件（AE）发生率为 47.6%（95%CI，33.1-62.0%）。
PD-1/PD-L1 抑制剂联合抗血管生成药物作为晚期非小细胞肺癌二线或更后线治疗具有良好的疗效和安全性。
https://www.crd.york.ac.uk/prospero/，标识符 CRD42023407559。
